Skip to main content
main-content
Top

15-10-2014 | Uterine cancer | Article

Surgical and systemic management of endometrial cancer: an international survey

Journal:
Archives of Gynecology and Obstetrics

Authors: Christina Fotopoulou, Robert Kraetschell, Sean Dowdy, Keiichi Fujiwara, Nobuo Yaegashi, Domenica Larusso, Antonio Casado, Sven Mahner, Thomas J. Herzog, Sean Kehoe, Ignace Vergote, David Scott Miller, Christian Marth, Shingo Fujii, Jalid Sehouli

Publisher: Springer Berlin Heidelberg

Abstract

Purpose

To ascertain the spectrum of clinical management of endometrial carcinoma (EC) the largest international survey was conducted to evaluate and identify differences worldwide.

Methods

After validation of a 15-item questionnaire regarding surgical and adjuvant treatment of EC in Germany, an English-adapted questionnaire was put online and posted to all the major gynecological cancer Societies worldwide for further distribution commencing in 2010 and continued for 26 months.

Results

A total of 618 Institutions around the world participated: Central Europe (CE), Southern Europe (SE), Northern Europe (NE), Asia and USA/Canada/UK. Both a therapeutic and staging value was attributed to systematic pelvic and paraaortic lymph node dissection (LND) in CE (74.6 %) and in Asia (67.2 %), as opposed to USA/UK where LND was mainly for staging purposes (53.5 %; p < 0.001). LND was performed up to the renal veins in CE in 86.8 %, in Asia in 80.8 %, in USA/UK in 51.2 % and in SE in 45.1 % (p < 0.001) of cases. In advanced disease, centers from Asia were treated most with adjuvant chemotherapy alone (93.6 %), as opposed to centers in SE, CE and UK/USA that employed combination chemo-radiotherapy in 90.9 % (p < 0.001) of cases. Paclitaxel/carboplatin was mostly used followed by doxorubicin/cisplatin (75 vs. 23.3 %; p < 0.001). In total, 94 % of all participants supported the concept of treating EC patients within appropriate clinical trials.

Conclusions

There is broad range in both the surgical and adjuvant treatment of EC across different countries. Large-scale multicenter prospective trials are warranted to establish consistent, evidence-based guidelines to optimize treatment worldwide.

Please log in to get access to this content

Related topics